Samsung Bioepis' Keytruda biosimilar meets equivalence endpoint in Phase III lung cancer trial
The Pharma Letter reports that Samsung Bioepis' biosimilar of Keytruda reached the equivalence endpoint in a Phase III trial in lung cancer.
“Samsung Bioepis’ Keytruda biosimilar meets equivalence endpoint in Phase III lung cancer trial”— The Pharma Letter
Samsung Bioepis' biosimilar of Keytruda has met the equivalence endpoint in a Phase III trial in lung cancer, according to a news item published by The Pharma Letter on 6 November 2026.
The item's available text consists of its headline only. It does not state the trial design, the number of participants, the size of any effect, the specific type of lung cancer studied, or the names of any investigators.
The report also does not say whether a regulatory submission has been made or approved, or when one might be expected. No statement from Samsung Bioepis is included in the text available.
Further details, including full trial results, were not provided in the source.
